Lourdes Gombau, head of the R&D Department, and Maria Riba, Business Development Manager, presented in the UK the last scientific article of the company, shedding light on the topic of compound intestinal toxicity.
MDCKII cells based in vitro system is a recommended model to evaluate blood-brain barrier permeability during CNS action novel compounds.
Inflammatory reactions of the intestinal tract are the result of a combination of hereditary, genetic and/or environmental factors that have been clustered in the inflammatory bowel disease (IBD). ReadyCell has available CacoReady and CacoGoblet to assay compounds inflammatory properties.
An investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. The CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).
The permeability assay protocol for Caco-2 cells serves as a cornerstone in understanding and predicting the intestinal absorption of pharmaceutical agents.
